Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy.
Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, Di Giacomo C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. Bibas M, et al. Am J Hematol. 2012 Aug;87(8):749-53. doi: 10.1002/ajh.23236. Epub 2012 Jun 20. Am J Hematol. 2012. PMID: 22718364 Free article. Clinical Trial.
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. Among authors: moioli c. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
17 results